TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM

The use of inhibitory checkpoint blockade in the management of glioblastoma has been studied in both preclinical and clinical settings. TIGIT is a novel checkpoint inhibitor recently discovered to play a role in cancer immunity. In this study, we sought to determine the effect of anti-PD-1 and anti-...

Descripción completa

Detalles Bibliográficos
Autores principales: Hung, Alice L., Maxwell, Russell, Theodros, Debebe, Belcaid, Zineb, Mathios, Dimitrios, Luksik, Andrew S., Kim, Eileen, Wu, Adela, Xia, Yuanxuan, Garzon-Muvdi, Tomas, Jackson, Christopher, Ye, Xiaobu, Tyler, Betty, Selby, Mark, Korman, Alan, Barnhart, Bryan, Park, Su-Myeong, Youn, Je-In, Chowdhury, Tamrin, Park, Chul-Kee, Brem, Henry, Pardoll, Drew M., Lim, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136875/
https://www.ncbi.nlm.nih.gov/pubmed/30221069
http://dx.doi.org/10.1080/2162402X.2018.1466769

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136875/
https://www.ncbi.nlm.nih.gov/pubmed/30221069
http://dx.doi.org/10.1080/2162402X.2018.1466769

Ejemplares similares